Reetoo

About Reetoo

Shenzhen Reetoo Biotechnology Co., Ltd., operating as Reetoo, is a high-tech enterprise in the in-vitro diagnostics (IVD) sector, founded on August 1, 2017, in Shenzhen, China. The company was founded by Li Qiaoliang, who holds a Ph.D. in artificial intelligence from Huazhong University of Science and Technology and serves as an IEEE member and a high-level talent in Shenzhen. His extensive background in AI, with over 120 published papers and numerous patents, directly informs the company's strategic focus.

Reetoo specializes in the development and manufacturing of fully automated and intelligent diagnostic products that integrate advanced artificial intelligence with medical testing. The company's business model centers on the research, development, production, and sales of these high-tech medical devices and consumables to a global market, with a significant presence across China. Its target clients are primarily clinical medical facilities and laboratories, which benefit from the automation and enhanced accuracy of diagnostic processes. The firm has established a substantial operational footprint, including a 25,000 square meter R&D and production base in Shenzhen.

The core of Reetoo's offering is its proprietary AI-based DeepCell engine, which enables high-precision cell identification across a wide range of human specimen types. This technology powers a comprehensive product line of intelligent diagnostic systems for various fields, including humoral analysis, prenatal diagnosis, pathology, and analyses of blood, leucorrhea, sperm, chromosomes, urine, and feces. These systems are designed to reshape the medical laboratory landscape by shifting from simple automation to AI-driven intelligence, thereby improving efficiency and accuracy. A notable product, the RT-F600 Vaginal Secretion Analyzer, has achieved a cell recognition accuracy of over 90% and won a man-machine competition for medical morphology. The company has secured significant venture capital, completing a Series B2 funding round in December 2023, with backers including LYFE Capital, Legend Star, and CMB International Capital.